China's mRNA vaccine triggers immune response in 95% of recipients in first stage of trial

Researchers also studied its use as a booster for those who received an inactivated-virus vaccine.

The Straits Times | I+D | Farmacia |

Leer noticia completa en el medio original
Spanish